Â鶹ӳ»­

Opening Session

8:30¨C8:50 a.m.

Welcome/Opening Remarks
James P. Allison, Ph.D.
Founding Director, The James P. Allison Institute

Special Announcement
Padmanee Sharma, M.D., Ph.D.
Director of Scientific Programs, The James P. Allison Institute

Remarks
William McKeon
President and CEO, Texas Medical Center

Session I: Breakthroughs in cancer vaccine and RNA biology

8:50¨C10:50 a.m.

Moderator 
Linghua Wang, M.D., Ph.D.

Keynote
Gary Ruvkun, Ph.D.
"Why are 16 of the 61 possible transfer RNAs missing from eukaryotic genomes?"

Catherine Wu, M.D.
"Personalized cancer vaccines: Updates and encouraging results"

Wen Jiang, M.D., Ph.D.
"The codemaker: Engineering the code of life for cancer vaccine and beyond"

Nina Bhardwaj, M.D., Ph.D.
"Navigating antigen heterogeneity and immune evasion in antigen-targeted immunotherapy"

Session II: The intersection of biology and chemistry for cancer immunotherapy

11:05 a.m.¨C1 p.m.

Moderator
Xi Chen, Ph.D.

Keynote
Carolyn Bertozzi, Ph.D.
"Biorthogonal chemistry for next-gen bioconjugate therapeutics"

Marcia Haigis, Ph.D.
"The role of metabolites in cancer and immunity"

Hojong Yoon, Ph.D.
"Expanding the druggable proteome with molecular glues"

Gabriel Rabinovich, Ph.D.
"Galectins as multifunctional targets in cancer: A sweet future for immunotherapy?"

Session III: Advances in cancer immunology for improving clinical outcomes

3¨C5:30 p.m.

Moderator 
Sangeeta Goswami, M.D., Ph.D.

Keynote
Andrea Schietinger, Ph.D.
"T cell differentiation and function in cancer"

Padmanee Sharma, M.D., Ph.D.
"Evaluating mechanisms to improve immune checkpoint therapy"

Betty Kim, M.D., Ph.D.
"Friend or foe: Reprogramming macrophages for cancer therapy"

Antoni Ribas, M.D., Ph.D.
"Targeted immunotherapy with PD-1 blockade"

Closing Keynote
Fred Ramsdell, Ph.D.
"From the Manhattan Project to autoimmune therapy"

Closing Remarks

5:30 p.m.

Elaine Mardis, Ph.D.